Scorpius Selected for Rapid Response Partnership Vehicle (RRPV) to Accelerate Development of Medical Countermeasures in Support of BARDA Page 1

Collaboration aims to accelerate the development of critical solutions to public health threats, including preparedness for pandemics and emerging infectious diseases

DURHAM, NC, September 9, 2024 (GLOBE NEWSWIRE) — Scorpius Holdings, Inc (NYSE American: (SCPX) Scorpius, Inc. (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization (“CDMO”), today announced that it has been selected as a member of the Biomedical Advanced Research and Development Authority (BARDA) Rapid Response Partnership Vehicle (RRPV). The RRPV supports BARDA in its mission to accelerate the development of medical countermeasures (MCMs) to address emerging biological threats such as pandemic influenza, infectious diseases, and other public health emergencies.